NCT00134485

Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia

Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Study of the Efficacy, Safety, and Tolerability of Fixed Combination Torcetrapib (CP-529,414) / Atorvastatin Administered Orally, Once Daily (QD) for Six Months, Compared With Maximally Tolerated Atorvastatin Therapy Alone, in Subjects With Heterozygous Familial Hypercholesterolemia

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 400 (planned)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To evaluate the efficacy and safety of torcetrapib/atorvastatin compared to atorvastatin alone in patients with heterozygous familial hypercholesterolemia

Detailed description

For additional information please call: 1-800-718-1021

Conditions

• Hypercholesterolemia, Familial
• Hyperlipidemia

Interventions

Type	Name	Description
DRUG	torcetrapib/atorvastatin
DRUG	atorvastatin

Timeline

• Start date: 2005-03-01
• Completion: 2006-03-01
• First posted: 2005-08-24
• Last updated: 2007-10-30

Locations

41 sites across 9 countries: United States, Australia, Canada, Denmark, France, Iceland, Norway, South Africa, Sweden